Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

High Serum Pepsinogen I and beta Helicobacter pylori Infection Are Risk Factors for Aspirin-Induced Gastroduodenal Injury

Shan J.a · Lei H.b · Shi W.a · Sun X.a · Tang Y.a · Ren C.a

Author affiliations

aDepartment of Gastroenterology, The 3rd People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu, and bClinical Medicine School, Southwest Medical University, Luzhou, China

Related Articles for ""

Dig Dis 2018;36:66–71

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 30, 2016
Accepted: April 21, 2017
Published online: June 09, 2017
Issue release date: October 2017

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Background: Whether gastric hyperchlorhydria and Helicobacter pylori infection contribute to aspirin-induced gastroduodenal injury still lacks evidence. Because serum pepsinogens (PGs) and gastrin-17 (G17) can reflect gastric acid secretion, this study intended to elucidate whether serum PGs, serum G17, and H. pylori infection are associated with aspirin-induced gastrointestinal injury. Summary: A total of 60 patients taking low-dose aspirin for more than 1 month were enrolled in this study. Serum PG I, PG II, and G17 were determined using ELISA. A 14C-urea breath test was used for the detection of an H. pylori infection. The modified Lanza score was used to evaluate the degree of gastroduodenal injury under endoscopy. The median serum PG I level was significantly higher in the intensive gastroduodenal injury (IGI) group compared to that in the mild gastroduodenal injury group (155.0 vs. 116.6 ng/mL, p = 0.006). The H. pylori infection rate was significantly higher in the IGI group (73 vs. 40%, p = 0.037). Receiver operator characteristic curves analysis revealed that the cutoff value of PG I was 123 ng/mL, with 80% sensitivity and 61.4% specificity. H. pylori infection combined with PG I at >123 ng/mL had an OR (95% CI) of 15.8 (2.4 ± 104.5) for the prediction of aspirin-induced gastroduodenal injury. Key Messages: Serum PG I and H. pylori infection could be used to identify potential high-risk aspirin-induced gastroduodenal injury patients.

© 2017 S. Karger AG, Basel


References

  1. Lauer MS: Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-1474.
  2. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT collaborative group. Lancet 1991;338:1345-1349.
  3. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
  4. Lanas A, Scheiman J: Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007;23:163-173.
  5. Lanas A, Polo-Tomas M, Casado-Arroyo R: The aspirin cardiovascular/gastrointestinal risk calculator - a tool to aid clinicians in practice. Aliment Pharmacol Ther 2013;37:738-748.
  6. Ho CW, Tse YK, Wu B, Mulder CJ, Chan FK: The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther 2013;37:819-824.
  7. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND: Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996;23:432-434.
  8. Iijima K, Koike T, Ara N, Nakagawa K, Kondo Y, Uno K, et al: Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol 2015;50:305-312.
  9. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T: Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol 2005;40:938-944.
  10. Derakhshan MH, El-Omar E, Oien K, Gillen D, Fyfe V, Crabtree JE, et al: Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol 2006;59:1293-1299.
  11. Iijima K, Koike T, Abe Y, Shimosegawa T: Cutoff serum pepsinogen values for predicting gastric acid secretion status. Tohoku J Exp Med 2014;232:293-300.
  12. el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE: Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993;34:1060-1065.
  13. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R: Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-786.
  14. Hart J, Hawkey CJ, Lanas A, Naesdal J, Talley NJ, Thomson AB, et al: Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2010;31:143-149.
  15. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS: Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010;32:831-839.
  16. Lanza FL, Graham DY, Davis RE, Rack MF: Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 1990;35:1494-1499.
  17. Sun L, Tu H, Liu J, Gong Y, Xu Q, Jing J, et al: A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population. Scand J Gastroenterol 2014;49:1164-1172.
  18. Cao Q, Ran ZH, Xiao SD: Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 2007;8:15-22.
  19. McQuaid KR, Laine L: Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-638.
  20. Germana B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, et al: Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis 2005;37:501-508.
  21. Shiraki M, Yamazaki Y, Kuroda T, Tanaka S, Miyata K: Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates. Osteoporos Int 2011;22:1717-1723.
  22. Sipponen P, Ranta P, Helske T, Kaariainen I, Maki T, Linnala A, et al: Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002;37:785-791.
  23. Dockray GJ: Topical review. Gastrin and gastric epithelial physiology. J Physiol 1999;518(pt 2):315-324.
  24. Agreus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P: Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009;44:564-570.
  25. Sostres C, Gargallo CJ, Lanas A: Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol 2014;20:9439-9450.
  26. Cui R, Zhou L: Helicobacter pylori infection: an overview in 2013, focus on therapy. Chin Med J (Engl) 2014;127:568-573.
  27. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 30, 2016
Accepted: April 21, 2017
Published online: June 09, 2017
Issue release date: October 2017

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.